HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTGâs proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services. Source
No articles found.
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
Scottline helps healthcare organizations establish a secure, agile digital infrast...
Scottline helps healthcare organizations establ...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics co...
CareDx, Inc., headquartered in Brisbane, Califo...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
Pulse Biosciences is a bioelectric medicine company pursuing commercial introducti...
Pulse Biosciences is a bioelectric medicine com...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
Join the National Investor Network and get the latest information with your interests in mind.